

Flávio Reis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8809446/publications.pdf>

Version: 2024-02-01

157
papers

4,843
citations

101543

36
h-index

123424

61
g-index

159
all docs

159
docs citations

159
times ranked

7507
citing authors

#	ARTICLE	IF	CITATIONS
1	The Signaling Pathway of TNF Receptors: Linking Animal Models of Renal Disease to Human CKD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3284.	4.1	16
2	1,8-Cineole ameliorates right ventricle dysfunction associated with pulmonary arterial hypertension by restoring connexin43 and mitochondrial homeostasis. <i>Pharmacological Research</i> , 2022, 180, 106151.	7.1	8
3	Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline. <i>Inflammation Research</i> , 2022, 71, 591-602.	4.0	7
4	Lactation as a programming window for metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13482.	3.4	32
5	Assessing Scientific Soundness and Translational Value of Animal Studies on DPP4 Inhibitors for Treating Type 2 Diabetes Mellitus. <i>Biology</i> , 2021, 10, 155.	2.8	2
6	A selective p53 activator and anticancer agent to improve colorectal cancer therapy. <i>Cell Reports</i> , 2021, 35, 108982.	6.4	20
7	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. <i>Biomedicines</i> , 2021, 9, 554.	3.2	2
8	Blueberry as an Attractive Functional Fruit to Prevent (Pre)Diabetes Progression. <i>Antioxidants</i> , 2021, 10, 1162.	5.1	19
9	Blueberry effects on prediabetic nephropathyâ€”a preclinical in vivo approach. <i>European Journal of Public Health</i> , 2021, 31, .	0.3	0
10	The impact of refined food processing on the kidneyâ€”preclinical evaluation. <i>European Journal of Public Health</i> , 2021, 31, .	0.3	0
11	Unhealthy lifestyles, environment, well-being and health capability in rural neighbourhoods: a community-based cross-sectional study. <i>BMC Public Health</i> , 2021, 21, 1628.	2.9	3
12	New Potential Biomarkers for Chronic Kidney Disease Managementâ€”A Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 43.	4.1	38
13	Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update. <i>Microorganisms</i> , 2021, 9, 53.	3.6	36
14	Editorial: Combating Redox Imbalance-Associated Complications With Natural Products. <i>Frontiers in Pharmacology</i> , 2021, 12, 802750.	3.5	4
15	Blueberry Counteracts Prediabetes in a Hypercaloric Diet-Induced Rat Model and Rescues Hepatic Mitochondrial Bioenergetics. <i>Nutrients</i> , 2021, 13, 4192.	4.1	10
16	The yin and yang faces of the mitochondrial deacetylase sirtuin 3 in age-related disorders. <i>Ageing Research Reviews</i> , 2020, 57, 100983.	10.9	23
17	Gut Microbiota Dysbiosisâ€”Immune Hyperresponseâ€”Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. <i>Microorganisms</i> , 2020, 8, 1514.	3.6	52
18	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities â€” Role of gut microbiota dysbiosis. <i>Ageing Research Reviews</i> , 2020, 62, 101123.	10.9	118

#	ARTICLE	IF	CITATIONS
19	Blueberry Consumption Challenges Hepatic Mitochondrial Bioenergetics and Elicits Transcriptomics Reprogramming in Healthy Wistar Rats. <i>Pharmaceutics</i> , 2020, 12, 1094.	4.5	4
20	Extracellular Vesicles and MicroRNA: Putative Role in Diagnosis and Treatment of Diabetic Retinopathy. <i>Antioxidants</i> , 2020, 9, 705.	5.1	23
21	Diet-induced rodent models of obesity-related metabolic disorders – A guide to a translational perspective. <i>Obesity Reviews</i> , 2020, 21, e13081.	6.5	37
22	P1581IMPACT OF ACHIEVING LDL CHOLESTEROL LOWER THAN 100 MG/DL WITH STATINS, ON LIPID PROFILE AND INFLAMMATION IN END-STAGE RENAL DISEASE PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
23	Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy. <i>Nutrients</i> , 2020, 12, 250.	4.1	41
24	Crescent-Like Lesions as an Early Signature of Nephropathy in a Rat Model of Prediabetes Induced by a Hypercaloric Diet. <i>Nutrients</i> , 2020, 12, 881.	4.1	10
25	The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes. <i>Life Sciences</i> , 2019, 234, 116738.	4.3	14
26	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1151.	3.7	21
27	Development of a Healthy Lifestyle Assessment Toolkit for the General Public. <i>Frontiers in Medicine</i> , 2019, 6, 134.	2.6	14
28	Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 1021-1039.	8.7	24
29	Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency. <i>Nutrients</i> , 2019, 11, 2216.	4.1	268
30	mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging 2018. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-3.	4.0	8
31	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-11.	4.0	15
32	Hepcidin in chronic kidney disease anemia. <i>Vitamins and Hormones</i> , 2019, 110, 243-264.	1.7	14
33	Weight loss achieved by bariatric surgery modifies high-density lipoprotein subfractions and low-density lipoprotein oxidation towards atheroprotection. <i>Clinical Biochemistry</i> , 2019, 63, 46-53.	1.9	15
34	Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1876-1897.	3.8	102
35	Influence of the 6-month physical activity programs on renal function in obese boys. <i>Pediatric Research</i> , 2018, 83, 1011-1015.	2.3	3
36	Discovery of a small-molecule protein kinase C δ -selective activator with promising application in colon cancer therapy. <i>Cell Death and Disease</i> , 2018, 9, 23.	6.3	25

#	ARTICLE	IF	CITATIONS
37	Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-17.	4.0	36
38	Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes. <i>Frontiers in Physiology</i> , 2018, 9, 1857.	2.8	75
39	Subtle thinning of retinal layers without overt vascular and inflammatory alterations in a rat model of prediabetes. <i>Molecular Vision</i> , 2018, 24, 353-366.	1.1	11
40	Therapeutic and Nutraceutical Potential of Rosmarinic Acid - Cytoprotective Properties and Pharmacokinetic Profile. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 00-00.	10.3	65
41	DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. <i>Molecular Oncology</i> , 2017, 11, 612-627.	4.6	33
42	Therapeutic strategies targeting oxidative stress to improve dyslipidemia and left ventricular hypertrophy. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 639-640.	0.5	2
43	Glucose and Lipid Dysmetabolism in a Rat Model of Prediabetes Induced by a High-Sucrose Diet. <i>Nutrients</i> , 2017, 9, 638.	4.1	38
44	Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	38
45	Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-14.	2.3	28
46	mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-4.	4.0	15
47	The HIF System Response to ESA Therapy in CKD Anemia. , 2017, , .		0
48	mTOR and Neuroinflammation. , 2016, , 317-329.		6
49	mTOR in Diabetic Nephropathy and Retinopathy. , 2016, , 379-393.		2
50	Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 3621-3640.	6.7	48
51	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 28.	4.1	11
52	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPICIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i194-i194.	0.7	1
53	Obesity and brain inflammation: a focus on multiple sclerosis. <i>Obesity Reviews</i> , 2016, 17, 211-224.	6.5	28
54	The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. <i>Obesity Reviews</i> , 2016, 17, 553-572.	6.5	33

#	ARTICLE	IF	CITATIONS
55	Renal riskâ€benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model â€ hypertension, anaemia, inflammation and drug dose. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 343-354.	1.9	10
56	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. <i>Biochimie</i> , 2016, 125, 150-162.	2.6	11
57	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. <i>Life Sciences</i> , 2016, 151, 147-156.	4.3	4
58	Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 1929-1941.	2.4	18
59	Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. <i>BMC Medicine</i> , 2016, 14, 163.	5.5	43
60	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 59, 63-70.	1.4	6
61	A fast and reliable method for GHB quantitation in whole blood by GCâ€MS/MS (TQD) for forensic purposes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 119, 139-144.	2.8	10
62	High sucrose consumption induces memory impairment in rats associated with electrophysiological modifications but not with metabolic changes in the hippocampus. <i>Neuroscience</i> , 2016, 315, 196-205.	2.3	22
63	Comparison of endogenous GHB concentrations in blood and hair in death cases with emphasis on the post mortem interval. <i>International Journal of Legal Medicine</i> , 2016, 130, 959-965.	2.2	10
64	Iron therapy in chronic kidney disease: Recent changes, benefits and risks. <i>Blood Reviews</i> , 2016, 30, 65-72.	5.7	28
65	Reactivation of wild-type and mutant p53 by tryptophan-derived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. <i>Oncotarget</i> , 2016, 7, 4326-4343.	1.8	37
66	Liver iron is a major regulator of hepcidin gene expression via <sc>BMP/SMAD</sc> pathway in a rat model of chronic renal failure under treatment with high r<sc>H</sc>u<sc>EPO</sc> doses. <i>BioFactors</i> , 2016, 42, 296-306.	5.4	8
67	Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. <i>Oncotarget</i> , 2015, 6, 36185-36201.	1.8	34
68	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. <i>PLoS ONE</i> , 2015, 10, e0124048.	2.5	33
69	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A â€œMe Tooâ€or â€œthe Special Oneâ€Antidiabetic Class?. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-28.	2.3	65
70	Characterization of solid lipid nanoparticles produced with carnauba wax for rosmarinic acid oral delivery. <i>RSC Advances</i> , 2015, 5, 22665-22673.	3.6	66
71	Solid Lipid Nanoparticles as Oral Delivery Systems of Phenolic Compounds: Overcoming Pharmacokinetic Limitations for Nutraceutical Applications. <i>Critical Reviews in Food Science and Nutrition</i> , 2015, 57, 00-00.	10.3	43
72	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. <i>BioMed Research International</i> , 2014, 2014, 1-17.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Remyelination in Multiple Sclerosis – How Close are We?. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	0
74	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 2014, 15, 8979-8997.	4.1	26
75	Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals. Mediators of Inflammation, 2014, 2014, 1-15.	3.0	97
76	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. BioMed Research International, 2014, 2014, 1-9.	1.9	12
77	Iron as the Key Modulator of Hpcidin Expression in Erythroid Antibody-Mediated Hypoplasia. BioMed Research International, 2014, 2014, 1-10.	1.9	5
78	Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetology and Metabolic Syndrome, 2014, 6, 42.	2.7	23
79	Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochemical Pharmacology, 2014, 88, 216-228.	4.4	35
80	Gamma-hydroxybutyric acid endogenous production and post-mortem behaviour – The importance of different biological matrices, cut-off reference values, sample collection and storage conditions. Journal of Clinical Forensic and Legal Medicine, 2014, 27, 17-24.	1.0	42
81	Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1454-1463.	3.8	64
82	Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. Metabolism: Clinical and Experimental, 2014, 63, 702-715.	3.4	19
83	Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment. Biochemical Pharmacology, 2014, 91, 61-73.	4.4	14
84	Haptoglobin 2 nd phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy. British Journal of Biomedical Science, 2014, 71, 79-81.	1.3	1
85	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression. , 2014, 5, 356-65.		12
86	Letter to the Editor: A potential mechanism for the pathogenesis of psoriasis <i>vulgaris</i> . International Journal of Dermatology, 2013, 52, 1429-1432.	1.0	0
87	Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovascular Diabetology, 2013, 12, 61.	6.8	56
88	Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovascular Diabetology, 2013, 12, 44.	6.8	66
89	Spatial memory impairments in a prediabetic rat model. Neuroscience, 2013, 250, 565-577.	2.3	80
90	Effects of Cyclosporine and Sirolimus on Insulin-Stimulated Glucose Transport and Glucose Tolerance in a Rat Model. Transplantation Proceedings, 2013, 45, 1142-1148.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Serum and Renal Tissue Markers of Nephropathy in Rats Under Immunosuppressive Therapy: Cyclosporine Versus Sirolimus. <i>Transplantation Proceedings</i> , 2013, 45, 1149-1156.	0.6	6
92	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	3.0	21
93	Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	22
94	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. <i>Disease Markers</i> , 2013, 35, 791-798.	1.3	45
95	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. <i>Disease Markers</i> , 2013, 35, 85-96.	1.3	32
96	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rEPO doses. <i>Hemodialysis International</i> , 2013, 17, n/a-n/a.	0.9	11
97	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. <i>Renal Failure</i> , 2013, 35, 1392-1398.	2.1	10
98	rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits. , 2013, , .		1
99	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. <i>Journal of Vascular Access</i> , 2013, 14, 335-341.	0.9	3
100	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. <i>Scientific World Journal</i> , The, 2013, 2013, 1-16.	2.1	7
101	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. <i>Disease Markers</i> , 2013, 34, 341-348.	1.3	56
102	New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. <i>Disease Markers</i> , 2013, 34, 341-8.	1.3	27
103	Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties. <i>International Journal of Molecular Sciences</i> , 2012, 13, 8482-8499.	4.1	28
104	Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2012, 4, 76.	0.6	18
105	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. <i>Renal Failure</i> , 2012, 34, 1355-1358.	2.1	4
106	Main Determinants of PON1 Activity in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2012, 36, 317-323.	3.1	16
107	Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 37-47.	6.7	15
108	Regular Physical Exercise as a Strategy to Improve Antioxidant and Anti-Inflammatory Status: Benefits in Type 2 Diabetes Mellitus. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-15.	4.0	77

#	ARTICLE	IF	CITATIONS
109	Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model. <i>Marine Drugs</i> , 2012, 10, 2661-2675.	4.6	43
110	Dexmedetomidine: Current Role in Anesthesia and Intensive Care. <i>Revista Brasileira De Anestesiologia</i> , 2012, 62, 118-133.	0.6	260
111	Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 454-463.	4.4	74
112	Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 143-8.	0.4	5
113	Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. <i>BJU International</i> , 2011, 107, 135-143.	2.5	14
114	Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 651-653.	1.9	1
115	Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. <i>Journal of Dermatology</i> , 2011, 38, 816-819.	1.2	6
116	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. <i>Hemodialysis International</i> , 2011, 15, 429-431.	0.9	4
117	Expression of Genes Encoding Extracellular Matrix Macromolecules and Metalloproteinases in Avian Tibial Dyschondroplasia. <i>Journal of Comparative Pathology</i> , 2011, 145, 174-186.	0.4	28
118	Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. <i>Cardiovascular Diabetology</i> , 2011, 10, 12.	6.8	198
119	Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2011, 3, 350.	0.6	24
120	Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). <i>Experimental Diabetes Research</i> , 2011, 2011, 1-12.	3.8	128
121	Apoptosis of Peripheral CD4 ⁺ T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. <i>Renal Failure</i> , 2011, 33, 138-143.	2.1	25
122	Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus. <i>Mediators of Inflammation</i> , 2011, 2011, 1-8.	3.0	38
123	C-reactive protein and leucocyte activation in psoriasis <i>vulgaris</i> according to severity and therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 789-796.	2.4	107
124	Circulating adipokine levels in Portuguese patients with psoriasis <i>vulgaris</i> according to body mass index, severity and therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1386-1394.	2.4	104
125	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor- α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. <i>British Journal of Dermatology</i> , 2010, 163, 1282-1290.	1.5	120
126	Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. <i>Renal Failure</i> , 2010, 32, 1073-1080.	2.1	10

#	ARTICLE	IF	CITATIONS
127	Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model. Mediators of Inflammation, 2010, 2010, 1-11.	3.0	11
128	Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators of Inflammation, 2010, 2010, 1-11.	3.0	143
129	Psoriasis Therapy and Cardiovascular Risk Factors. American Journal of Clinical Dermatology, 2010, 11, 423-432.	6.7	36
130	The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option?. Kidney International, 2010, 77, 1055-1057.	5.2	13
131	Effect of Recombinant Human Erythropoietin in a Rat Model of Moderate Chronic Renal Failure - Focus on Inflammation, Oxidative Stress and Function/Renoprotection. The Open Drug Discovery Journal, 2010, 2, 25-32.	0.7	1
132	Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biology and Therapy, 2009, 8, 1615-1622.	3.4	19
133	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	1.4	41
134	Characterization of a Rat Model of Moderate Chronic Renal Failure – Focus on Hematological, Biochemical, and Cardio-Renal Profiles. Renal Failure, 2009, 31, 833-842.	2.1	8
135	Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition, 2009, 25, 330-339.	2.4	91
136	Erythropoietin Promotes Deleterious Cardiovascular Effects and Mortality Risk in a Rat Model of Chronic Sports Doping. Cardiovascular Toxicology, 2009, 9, 201-210.	2.7	22
137	Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine. Transplantation Proceedings, 2009, 41, 868-873.	0.6	37
138	Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. Journal of Dermatological Science, 2009, 55, 202-204.	1.9	53
139	Treadmill running and swimming imposes distinct cardiovascular physiological adaptations in the rat: Focus on serotonergic and sympathetic nervous systems modulation. Acta Physiologica Hungarica, 2008, 95, 365-381.	0.9	21
140	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	3.1	36
141	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	1.4	4
142	Dual Effect of Nitrate Therapy for Cyclosporine-Induced Hypertension on Vascular and Platelet Morphofunctional Markers; An Animal Model. Transplantation Proceedings, 2007, 39, 2501-2506.	0.6	5
143	Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy. Transplantation Proceedings, 2007, 39, 2494-2500.	0.6	15
144	Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type) Tj ETQq0 0 Q 1gBT /Overlock 10 T	1.1	40

#	ARTICLE	IF	CITATIONS
145	CURATIVE ISOSORBIDE-5-MONONITRATE TREATMENT, IN OPPOSITION TO THE BENEFICIAL PREVENTIVE ONE, AGGRAVATES THE PROTHROMBOTIC AND PROCONSTRICTOR STATE IN CYCLOSPORINE-INDUCED HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 640-648.	1.9	4
146	Platelet Hyperactivation in Maintained Growth Hormone-Deficient Childhood Patients after Therapy Withdrawal as a Putative Earlier Marker of Increased Cardiovascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 98-105.	3.6	5
147	Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. <i>Life Sciences</i> , 2005, 77, 2514-2528.	4.3	14
148	Vitreous humour as a complementary sample to blood for the detection/confirmation of diazepam: ante-mortem and post-mortem studies in an animal model. <i>Human and Experimental Toxicology</i> , 2004, 23, 571-577.	2.2	20
149	Impairment of vascular and platelet levels of nitric oxide and cyclic guanosine-3',5'-monophosphate in cyclosporin A-induced hypertensive rats. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 43-50.	1.9	6
150	Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3',5'-monophosphate disturbances. <i>Thrombosis Research</i> , 2003, 110, 107-115.	1.7	8
151	Circadian and seasonal variation of endogenous ubiquinone plasma level. <i>Chronobiology International</i> , 2002, 19, 599-614.	2.0	8
152	Cardiovascular effects of cyclosporin treatment in an experimental model. <i>Revista Portuguesa De Cardiologia</i> , 2002, 21, 141-55.	0.5	12
153	Platelet Activation is Increased in Cyclosporin A-Induced Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 56-64.	1.9	16
154	THE DISTRIBUTION OF CATECHOLAMINES BETWEEN PLASMA AND PLATELETS IN CYCLOSPORIN A-INDUCED HYPERTENSIVE RATS. <i>Pharmacological Research</i> , 2000, 41, 129-135.	7.1	12
155	The Peripheral Serotonergic System and Platelet Aggregation in Cyclosporin A-Induced Hypertensive Rats. <i>Thrombosis Research</i> , 1999, 96, 365-372.	1.7	12
156	Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes. <i>International Journal of Interferon, Cytokine and Mediator Research</i> , 0, , 75.	1.1	8
157	The role of inflammation in diabetic cardiomyopathy. <i>International Journal of Interferon, Cytokine and Mediator Research</i> , 0, , 59.	1.1	13